Ramona F. Swaby - Concepedia

Author

Ramona F. Swaby

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

R Swaby, R. F. Swaby, R. Swaby, R.F. Swaby, Ramona F Swaby, Ramona F. Swaby, Ramona Swaby

123

Publications

5.6K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Fox Chase Cancer Center Yale Cancer Center Institute of Cancer Research Fondazione IRCCS Istituto Nazionale dei Tumori

About

Ramona F. Swaby is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	33	3.5K
2	Health Sciences	11	12	421
3	Engineering	1	1	117
4	Public Health	1	1	12
5	Biochemistry	1	1	25

Ramona F. Swaby

Publications

5.3K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau, The Lancet MedicinePathologyHead And Neck CancerCancer TreatmentNeck Oncology	2018	1.6K
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response Evandro de Azambuja, Andrew Holmes, Martine Piccart, The Lancet Oncology Survival OutcomesBreast OncologyMedicinePathologyPathological Complete Response	2014	452
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study Kevin J. Harrington, Barbara Burtness, Richard Greil, Journal of Clinical Oncology	2022	438
Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629) Jean‐Jacques Grob, René González, Nicole Basset‐Séguin, Journal of Clinical Oncology	2020	270
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Xavier Pivot, Alexey Manikhas, Zurawski Bogdan, Journal of Clinical Oncology	2015	248
Activity of Suberoylanilide Hydroxamic Acid Against Human Breast Cancer Cells with Amplification of Her-2 Purva Bali, Michael Pranpat, Ramona F. Swaby, Clinical Cancer Research	2005	186
Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial Brett Hughes, Eva Muñoz‐Couselo, Laurent Mortier, Annals of Oncology	2021	179
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial Jean‐Pascal Machiels, Yungan Tao, Lisa Licitra, The Lancet Oncology Concurrent ChemoradiotherapyNeoadjuvant TherapySquamous Cell CarcinomaMedicineHead And Neck Cancer	2024	174
CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial Kim A. Reiss, Mathew G. Angelos, E. Claire Dees, Nature Medicine Solid TumorsCar-macrophage TherapyMedicineImmunologyBreast Cancer	2025	124
Determination of Cancer Risk Associated with Germ Line BRCA1 Missense Variants by Functional Analysis Marcelo A. Carvalho, Sylvia M. Marsillac, Rachel Karchin, Cancer Research EngineeringGeneticsGenetic EpidemiologyPathologyCancer Risk Associated	2007	117

Page 1